Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Trent

Showing results (61-70 of 79) with videos related to

Pageof 8
Sort By:
BMC Cancer|June 7, 2022
Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinibJames C H Yang, Marcia S Brose, Gilberto Castro, et al.
The Oncologist|December 10, 2020
Optimal Avapritinib Treatment Strategies for Patients with Metastatic or Unresectable Gastrointestinal Stromal TumorsCissimol P Joseph, Sarah N Abaricia, Michelle A Angelis, et al.
Journal for Immunotherapy of Cancer|August 16, 2023
Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burdenVaia Florou, Charalampos S Floudas, Asaf Maoz, et al.
Annals of Surgical Oncology|October 31, 2006
Surgical resection of gastrointestinal stromal tumors after treatment with imatinibRobert H I Andtbacka, Chaan S Ng, Courtney L Scaife, et al.
The Journal of Clinical Investigation|December 7, 2007
An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxicAriel Fernández, Angela Sanguino, Zhenghong Peng, et al.
Cancers|March 6, 2021
Unmet Medical Needs and Future Perspectives for Leiomyosarcoma Patients-A Position Paper from the National LeioMyoSarcoma Foundation (NLMSF) and Sarcoma Patients EuroNet (SPAEN)Bernd Kasper, Annie Achee, Kathrin Schuster, et al.
The Oncologist|January 16, 2021
Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of TherapySuzanne George, Robin L Jones, Sebastian Bauer, et al.
Cancer|November 15, 2024
Sorafenib or anthracycline-based chemotherapy for progressive desmoid tumorsPhilippos Apolinario Costa, Arshia Arora, Yannelys Fernandez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2022
Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III TrialSebastian Bauer, Robin L Jones, Jean-Yves Blay, et al.
Leukemia Research|November 28, 2017
Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot studyRonan T Swords, Diana Azzam, Hassan Al-Ali, et al.
Pageof 8

Showing results (61-70 of 79) with videos related to

Sort By:
Pageof 8
BMC Cancer|June 7, 2022
Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinibJames C H Yang, Marcia S Brose, Gilberto Castro, et al.
The Oncologist|December 10, 2020
Optimal Avapritinib Treatment Strategies for Patients with Metastatic or Unresectable Gastrointestinal Stromal TumorsCissimol P Joseph, Sarah N Abaricia, Michelle A Angelis, et al.
Journal for Immunotherapy of Cancer|August 16, 2023
Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burdenVaia Florou, Charalampos S Floudas, Asaf Maoz, et al.
Annals of Surgical Oncology|October 31, 2006
Surgical resection of gastrointestinal stromal tumors after treatment with imatinibRobert H I Andtbacka, Chaan S Ng, Courtney L Scaife, et al.
The Journal of Clinical Investigation|December 7, 2007
An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxicAriel Fernández, Angela Sanguino, Zhenghong Peng, et al.
Cancers|March 6, 2021
Unmet Medical Needs and Future Perspectives for Leiomyosarcoma Patients-A Position Paper from the National LeioMyoSarcoma Foundation (NLMSF) and Sarcoma Patients EuroNet (SPAEN)Bernd Kasper, Annie Achee, Kathrin Schuster, et al.
The Oncologist|January 16, 2021
Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of TherapySuzanne George, Robin L Jones, Sebastian Bauer, et al.
Cancer|November 15, 2024
Sorafenib or anthracycline-based chemotherapy for progressive desmoid tumorsPhilippos Apolinario Costa, Arshia Arora, Yannelys Fernandez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2022
Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III TrialSebastian Bauer, Robin L Jones, Jean-Yves Blay, et al.
Leukemia Research|November 28, 2017
Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot studyRonan T Swords, Diana Azzam, Hassan Al-Ali, et al.
Pageof 8